Carmat - Asset Resilience Ratio
Carmat (ALCAR) has an Asset Resilience Ratio of 39.63% as of June 2012. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Carmat (ALCAR) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2017)
This chart shows how Carmat's Asset Resilience Ratio has changed over time. See Carmat (ALCAR) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Carmat's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Carmat (ALCAR) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €10.15 Million | 39.63% |
| Total Liquid Assets | €10.15 Million | 39.63% |
Asset Resilience Insights
- Very High Liquidity: Carmat maintains exceptional liquid asset reserves at 39.63% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Carmat Industry Peers by Asset Resilience Ratio
Compare Carmat's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Medacta Group SA
SW:MOVE |
Medical Devices | 0.86% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Respiri Ltd
AU:RSH |
Medical Devices | 0.46% |
|
Human Xtensions Ltd
TA:HUMX |
Medical Devices | 29.83% |
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
Annual Asset Resilience Ratio for Carmat (2009–2017)
The table below shows the annual Asset Resilience Ratio data for Carmat.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.00% | €0.00 ≈ $0.00 |
€69.85 Million ≈ $81.66 Million |
-- |
| 2016-12-31 | 21.36% | €8.01 Million ≈ $9.36 Million |
€37.49 Million ≈ $43.83 Million |
-28.49pp |
| 2014-12-31 | 49.85% | €7.00 Million ≈ $8.18 Million |
€14.04 Million ≈ $16.42 Million |
+23.02pp |
| 2011-12-31 | 26.83% | €10.04 Million ≈ $11.74 Million |
€37.43 Million ≈ $43.76 Million |
-6.79pp |
| 2010-12-31 | 33.61% | €7.07 Million ≈ $8.27 Million |
€21.05 Million ≈ $24.61 Million |
+25.99pp |
| 2009-12-31 | 7.63% | €461.45K ≈ $539.49K |
€6.05 Million ≈ $7.08 Million |
-- |
About Carmat
Carmat SA designs and develops total artificial heart for patients with advanced heart failure in France and internationally. The company offers Aeson, an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The company was incorporated in 2008 and is headquartered in Vélizy-Villacoublay, France.